2-Sep-2026
Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference
Business Wire (Mon, 31-Aug 4:01 PM ET)
Business Wire (Thu, 30-Jul 4:01 PM ET)
Omnicell Lifts 2026 Outlook on Strong Q2 Profitability and Expanding Service Revenues
Market Chameleon (Thu, 30-Jul 4:03 AM ET)
Omnicell Announces Second Quarter 2026 Financial Results
Business Wire (Thu, 30-Jul 6:30 AM ET)
Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026
Business Wire (Mon, 13-Jul 4:01 PM ET)
Nnamdi Njoku Appointed President of Omnicell
Business Wire (Wed, 1-Jul 8:15 AM ET)
Omnicell Selects Dan Mandoli to Lead Specialty Pharmacy Services Business
Business Wire (Mon, 8-Jun 8:30 AM ET)
Omnicell Raises 2026 Profit Guidance After Robust Q1 Performance and Product Momentum
Market Chameleon (Tue, 28-Apr 7:07 AM ET)
Omnicell Raises 2026 Profit Guidance as Non-GAAP EBITDA Jumps 89% on Strong Q1 Performance
Market Chameleon (Tue, 28-Apr 4:22 AM ET)
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Omnicell trades on the NASDAQ stock market under the symbol OMCL.
As of September 2, 2026, OMCL stock price climbed to $34.71 with 601,804 million shares trading.
OMCL has a beta of 1.28, meaning it tends to be more sensitive to market movements. OMCL has a correlation of 0.09 to the broad based SPY ETF.
OMCL has a market cap of $1.58 billion. This is considered a Small Cap stock.
Last quarter Omnicell reported $312 million in Revenue and $.94 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $.50.
In the last 3 years, OMCL traded as high as $61.44 and as low as $22.66.
The top ETF exchange traded funds that OMCL belongs to (by Net Assets): IJR, VTI, IWM, VB, VBR.
OMCL has underperformed the market in the last year with a price return of +6.5% while the SPY ETF gained +19.8%. OMCL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -19.6% and -3.5%, respectively, while the SPY returned +1.1% and -0.3%, respectively.
OMCL support price is $33.65 and resistance is $35.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OMCL shares will trade within this expected range on the day.